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A B S T R A C T   
Background: Preclinical studies recently showed that the mineralocorticoid antagonist spironolactone acts also as 
an antagonist of the NRG1-ERBB4 signaling pathway and improves schizophrenia-like behaviour in Nrg1 
transgenic mouse model. As this signaling pathway is critically linked to the pathophysiology of schizophrenia, 
especially in the context of working-memory dysfunction, spironolactone may be a novel treatment option for 
patients with schizophrenia targeting cognitive impairments. 
Aims: To evaluate whether spironolactone added to an ongoing antipsychotic treatment improves cognitive 
functioning in schizophrenia. 
Methods: The add-on spironolactone for the treatment of schizophrenia trial (SPIRO-TREAT) is a multicenter 
randomized, placebo-controlled trial with three arms (spironolactone 100 mg, spironolactone 200 mg and pla-
cebo). Schizophrenia patients are treated for three weeks and then followed-up for additional nine weeks. As 
primary outcome, we investigate changes in working memory before and at the end of the intervention phase. 
We will randomize 90 patients. Eighty-one patients are intended to reach the primary endpoint measure at the 
end of the three-week intervention period. Secondary endpoints include other measures of cognition, psycho-
pathology, safety measures and biological measures. 
Conclusions: SPIRO-TREAT is the first study evaluating the efficacy of the mineralocorticoid receptor antagonist 
spironolactone to improve cognitive impairments in schizophrenia patients targeting the NRG1-ERBB4 signaling 
pathway. With SPIRO-TREAT, we intend to investigate a novel treatment option for cognitive impairments in 
schizophrenia that goes beyond the established concepts of interfering with dopaminergic neurotransmission as 
key pathway in schizophrenia treatment. 
Clinical trial registration: International Clinical Trials Registry Platform: http://apps.who.int/trialsearch/Trial2. 
aspx?TrialIDEUCTR2014-001968-35-DE  
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1. Introduction 
Novel treatment options for schizophrenia that are based in the 
pathophysiology of the disorder are lacking and pharmaceutical com-
panies are increasingly withdrawing from the field [1]. Especially for 
cognitive symptoms with their known significant impeding impact on 
patients’ quality of life, effective pharmacological treatment options are 
yet not available [2,3]. While positive or depressive symptoms are 
viewed to be effectively treatable with available antipsychotics and 
antidepressants [4,5], the efficacy of such compounds in the manage-
ment of cognitive symptoms is not persuasive [6–11]. 
In that regard, one frequently discussed signaling pathway is the 
neuregulin (NRG1)-ERBB4 pathway that is critically linked to the 
pathophysiology of schizophrenia and especially to the occurrence of 
working-memory dysfunction [12–15]. Notably, both the 
membrane-bound ligand NRG1 and its cognate receptor ERBB4 were 
identified as potential risk genes for schizophrenia [16]. A critical 
involvement of this pathway in the pathophysiology of schizophrenia is 
further supported by post-mortem findings showing an increased 
expression of NRG1 [17,18], a relationship between ERBB4 splicing and 
parvalbumin interneuron activity [12], and a NRG1 induced hyper-
phosphorylation of ERBB4 [19]. Mouse models with overexpressed 
NRG1-levels show schizophrenia-like behavior like increased hyperac-
tivity, reduced social interaction and cognitive impairments [15,20–22]. 
Remarkably, these deficits were reversible when NRG1-overexpression 
was turned off [23]. This effect was accompanied by restoring normal 
synaptic functioning in glutamatergic axon terminals [23], supporting 
the idea that such therapeutic interventions in the adult brain may also 
restore impaired synaptic functioning [24]. Related to this finding, it has 
been shown that NRG1 is clearly required for normal behavior, that this 
pathological effect can be reversed, and that overexpressed NRG1-levels 
as a consequence of gain-of-function mutations are risk factors for 
schizophrenia in mouse models [25]. 
In light of the evidence that NRG1-ERBB4 pathway represents a 
promising target for a new therapeutic concept in schizophrenia [19] 
and that the repurposing of existing drugs offers a fast track to clinical 
applications, we recently published a preclinical study. In this preclin-
ical study, we applied a drug repurposing strategy to identify com-
pounds that can improve schizophrenia-relevant behavioral phenotypes 
in an Nrg1 transgenic mouse model. We screened the NIH-NCC com-
pound library of approved drugs for chemical modulators that cause 
changes in the activity of NRG1-ERBB4 signaling, using a cell-based 
assay [26]. From this screen, the mineralocorticoid antagonist spi-
ronolactone was recovered as inhibitor of ERBB4 activity and reduced 
phosphorylation levels of ERBB4 both in vitro in human heterologous 
T-47D cells and in vivo in Nrg1 transgenic mice [26]. Spironolactone has 
been introduced for the treatment of heart failure or hyperaldosteronism 
more than 50 years ago. In our preclinical study, spironolactone caused 
an increase of enhanced inhibitory neurotransmission in organotypic 
slice cultures, supporting an ERBB4 mediated mode-of-action in inhib-
itory interneurons. To test behavioral improvements, Nrg1 transgenic 
mice were chronically treated with spironolactone and tested in exper-
imental paradigms reflecting schizophrenia-relevant phenotypes in ro-
dents. Notably, spironolactone-treated Nrg1 transgenic mice displayed 
improved aspects of positive symptoms as well as improvements in 
working memory functions [26]. SPIRO-TREAT is the first study eval-
uating the efficacy and safety of the mineralocorticoid receptor antag-
onist spironolactone added to an ongoing antipsychotic treatment to 
improve working memory deficits in patients with schizophrenia. 
2. Materials and methods 
2.1. Study design 
SPIRO-TREAT is a multi-centre trial with three German sites 
involved. The study is designed as a prospective, randomized, placebo- 
controlled, double blind, three-arm trial with two arms investigating 
an active compound (spironolactone 100 mg or 200 mg) and one pla-
cebo arm. The clinical trial has been approved by the local ethics com-
mittees and the medical regulatory authorities in Germany (Federal 
Institute for Drugs and Medical Device (Bundesinstitut für Arzneimittel 
und Medizinprodukte (BfArM)). Prior to the inclusion of the first patient, 
the study was registered in the EU Clinical Trials Register (https://www. 
clinicaltrialsregister.eu/ctr-search/search?queryeudract_numbe 
r:2014-001968-35) and the International Clinical Trials Registry Plat-
form (ICTRP, http://apps.who.int/trialsearch/Trial2.aspx?Tr 
ialIDEUCTR2014-001968-35-DE). 
2.2. Study sites 
The following clinical trial sites are involved: Coordinating site: 
Department of Psychiatry and Psychotherapy of the Ludwig-Maximilian 
University Munich (Coordinating Investigators (CIs): P. Falkai; A. 
Hasan), Department of Psychiatry and Psychotherapy of the Technical 
University Munich (Principal Investigator (PI): S. Leucht) and Depart-
ment of Psychiatry and Psychotherapy of the University of Regensburg 
(PI: B. Langguth). All involved investigators performing patients’ ratings 
are trained for a standardized evaluation of the patients. 
2.3. Study population 
Inclusion criteria are defined as follows: 1) In- and outpatients (men 
and women) aged between 18 and 65 with a primary diagnosis of 
schizophrenia according to ICD-10 confirmed by the Mini-International 
Neuropsychiatric Interview [27]. 2) Participants are able to sign 
informed consent, 3) must receive a stable antipsychotic treatment for at 
least one week, 4) must not be treated with more than two antipsy-
chotics, 5) must have a PANSS total 75, 6) must have a duration of 
illness of at least six months. 7) Female participants must have a nega-
tive pregnancy test (serum) at baseline and must use a method of 
contraception that is medically approved by the health authority. 
Exclusion criteria are: 1) Incapacity to give informed consent, 2) 
suicidality or endangerment of others, 3) severe somatic or neurological 
comorbidities 4) history or assumption of relevant non-compliance that 
interferes with the ability to participate in a clinical trial, 5) current 
antipsychotic treatment with clozapine or an antipsychotic with exclu-
sive renal elimination (e.g. amisulpride), 6) planned initiation of a 
treatment with an antidepressant or mood stabilizer during the inter-
vention period (a prior treatment with an non-renal eliminated antide-
pressant or a mood-stabilizer other than lithium is permitted), 7) 
diagnoses of drug dependency other than tobacco or caffeine within the 
last 6 months prior to inclusion, 8) history of seizures (only relevant for 
the physiological investigation with transcranial magnetic stimulation 
(TMS)), 9) documented intolerance to a treatment with spironolactone 
or placebo capsules, 10) acute kidney failure or anuria, or severe kidney 
insufficiency (creatinine clearance < 30 ml/min per 1.73 m2 or serum 
creatinine > 1.8 mg/dl), 11) clinically relevant hyperkalemia or hypo-
natremia, 12) clinically relevant hypotension (RR < 100/80 mmHg), 
simultaneous use of potassium-sparing diuretics, ACE inhibitors, ATII- 
antagonists, non-steroidal anti-inflammatory drugs (NSAID), thiazide 
diuretics, carbenoxolone, digoxin or neomycin, 13) coercive treatment 
14) treatment-resistant or treatment-naïve schizophrenia, 14) insuffi-
cient understanding of German language, 15) pregnancy and 16) absent 
safe and approved methods of contraception. 
2.4. Intervention 
Participants are randomized into either one out of two interventional 
groups (spironolactone 100 mg or 200 mg per day) or one control group 
(placebo) and are treated for three weeks (see Fig. 1). In contrast to the 
preclinical study – where a higher dose of spironolactone was admin-
istered to mice each day and which corresponds to a calculated average 
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dose of 400 mg spironolactone for patients [26] – we use lower dosages 
of 100 mg and 200 mg for this proof-of-concept trial. The reasons for this 
approach are that the application of 400 mg/day would need a long 
titration period in humans and that such a dose would significantly in-
crease the risk for life-threatening hyperkalemia and potential cardiac 
complications (especially in combination with QTc-prolonging anti-
psychotics). In every group, participants receive two identical capsules 
per day to maintain the blind. In group I (spironolactone 100 mg), 
participants receive at the first day 1 capsule with 50 mg spironolactone 
and 1 capsule with placebo and from day 2 to day 21 two capsules with 
50 mg spironolactone in each per day. In group II (spironolactone 200 
mg), participants receive at the first day one capsule with 50 mg spi-
ronolactone and one capsule with placebo, at day 2 two capsules with 
50 mg spironolactone (100 mg in total), at day 3 one capsule with 50 mg 
spironolactone and one capsule with 100 mg spironolactone (150 mg in 
total) and from day 4 to day 21 two capsules with 100 mg spironolactone 
per day (200 mg in total). In group III (placebo), participants receive 
every day two capsules with placebo. A discontinuation of the allocated 
intervention, as well as the need for a long-term dose reduction result 
both in a drop-out. Adherence is assessed by counting the capsules and 
strategies to improve the adherence include the conduction of at least 
three study visits per week during the intervention period and the pos-
sibility to contact patients via phone in cases of no show-up. Patients 
who discontinue medication or drop-out for other reasons are offered to 
perform the V10 visit 
Central randomization was performed block wise stratified by study 
centre at MSZ using nQuery Advisor 7.0. The randomization list was 
then forwarded to the pharmacy of the University Hospital Munich for 
labeling and distributing of blinded study medication. Randomization 
will take place as the patients are assigned the next available patient 
number in chronological order and receive the corresponding medica-
tion kit, which already contains the correct blinded medication. Safety 
envelopes for emergency unblinding are available at all centres and the 
integrity of the envelopes is monitored until study end. In order to 
preserve the allocation concealment, the randomization sequence will 
not be shared with the study personnel. Please see Table 1 for the syn-
opsis of study visits and assessments. 
Unblinding of study medication before database hardlock may only 
occur on an individual basis if the information can help treat an (S)AE 
and for safety reasons. The decision to unblinding is at the discretion of 
the investigator. For this purpose, investigators will have sealed enve-
lopes comprising the information on the type of medication stored used 
for a given randomization number. All sites will have one sealed enve-
lope for each randomization number. In the case of a medical emergency 
as described below, the envelope must be opened and the treatment 
assignment of the respective patient will be unblinded. 
Study medication will be applied as an add-on to standard care as 
defined in the study design. The concurrent medication will be docu-
mented in the case report form (CRF). If a second antipsychotic is used, a 
maximum of 1000 chlorpromazine equivalents should not be exceeded 
and the target symptom (e.g. sleeping disorder) is to be defined pre-
cisely. Lorazepam (max. 3 mg/d), lormetazepam (max. 3 mg/d), diaz-
epam (max. 20 mg/d), zopiclone (max. 7.5 mg/d) and biperiden (max. 4 
mg/d) are approved as concurrent medication. The initiation of anti-
depressants or antiepileptic drugs in the three-week intervention period 
is not allowed. 
The study flow-chart is presented in Fig. 2. The pre-screening and the 
screening phases can take place in the two weeks prior to randomiza-
tion. The total study period after randomization is 12 weeks for every 
patient, including 3 weeks of intervention and 9 weeks of naturalistic 
follow-up. 
2.5. Endpoints and endpoint rationale 
The primary endpoint is change in working memory performance 
assessed by the n-back test (2-back level, hit rate) before and after the 
intervention period. The n-back test is a well-established method for 
examining working memory [28] and impairments in working-memory 
are core symptoms of schizophrenia [29]. In SPIRO-TREAT we use a 
computerized (Presentation Version 16.5, https://www.neurobs.com/) 
n-back paradigm with three loads (0-back, 1-back, 2-back). Each load is 
presented in six separate blocks with 14 trials each. On a standard 
computer screen participants are presented with a number from 1 to 4 
every 1800 ms (with numbers being displayed for 400 ms) and asked to 
press the respective of four response buttons to either the number 
currently presented (0-back), or the number from the trial before 
(1-back), or the number from two trials before (2-back). For 0-back there 
are 14 pre-defined targets are defined per experimental block (with a 
total of 84 targets), for the 1-back - 13 targets (with a total of 78 targets), 
and for the 2-back - 12 targets (with a total of 72 targets) [30]. Exper-
imental blocks occur in a pseudorandomized order and prior to each 
block the instruction for the following task is presented. The sums of 
hits, errors and missing trials for each load, as well as the respective 
reaction times are recorded. More details regarding the used n-back are 
described elsewhere [30]. 
Secondary endpoints include the change after the intervention period 
in the remaining n-back test results (hit rates, error rates, and reaction 
times) and the change after the follow-up period in n-back performance 
and in other cognitive functions. The verbal declarative memory 
assessed by the German version of the Rey Auditory Verbal Learning 
Test (Verbaler Lern-und Merkfahigkeitstest, VLMT) [31], the complex 
visual scanning, motor speed, the ability to shift strategies assessed by 
the Trail-Making-Test A (TMT-A) and TMT-B [32] and measures of 
sustained and selective attention assessed by d2-attention test [33] were 
used for further cognitive testing. Psychopathological measures include 
the change in Positive and Negative Syndrome Scale (PANSS) [34] and 
the frequency of remitters according to the Andreasen criteria [35]. 
Depressive symptoms are assessed using the Calgary Depression Scale 
for Schizophrenia (CDSS) [36], disease severity using the Clinical Global 
Impression scale (CGI) [37] and general functioning using the Global 
Assessment of Functioning scale (GAF) [38]. Differences between both 
active study groups in all outcome measures are assessed. Secondary 
endpoints are assessed directly after the intervention and after the 
naturalistic follow-up. 
Safety measures include physical examinations, electrocardiography 
(ECG), study laboratory, blood pressure and heart frequency, as well as 
Fig. 1. Sequence of trial milestones per patient.  
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Table 1 
Frequency and scope of study visits.  
Study Visite  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 
Phase Screening Baseline Intervention Post Intervention Close-Out 
Day   14 bis   1 0 2 5 7 9 11 14 16 19 21 25 84 
Inclusion/Exclusion criteria X X            
MINI-Plus interview X             
Informed consent X             
Demography  X            
Psychiatric history  X            
Medical history  X            
Randomization  X            
(Serious) adverse events  X X X X X X X X X X Xa X 
Co-medication  X   X   X   X  X 
n-Back  X         X  X 
Neuropsychology (VLMT, TMT, d2)  X         X  X 
SiAS  X         X  X 
PANSS X X X  X   X   X  X 
CDSS  X         X  X 
CGI  X X  X   X   X  X 
GAF  X         X  X 
ECG  X         X  X 
Physical examination  X X        X  X 
Vital signs (BP, HR) X X X  X   X   X X X 
BMI, waist circumference  X         X  X 
Study laboratory  X X X X X X X X X X X X 
mRNA (optional)  X         X   
TMS (optional)  X         X   
Pregnancy test  X            
Dispense study medication  X   X   X      
Return study medication     X   X   X   
MINI-Plus: MINI-Plus Interview for ICD-10 and DSM-IV diagnosis; PANSS: Positive and Negative Syndrome Scale in Schizophrenia; CDSS: Calgary Depression Rating 
Scale for Schizophrenia; CGI: Clinical Global Impression; GAF: Global Assessment Scale of Functioning; SiAS: Simpson Angus Scale for EPMS, ECG: electrocardiogram; 
BP: blood pressure; HR: heart rate; BMI: Body Mass Index, VLMT: Verbaler Lern-und Merkfahigkeitstest (German version of the California Verbal Learning Test); TMT: 
Trail-Making-Test; d2: d2-attention test, TMS: transcranial magnetic stimulation; (S)AE: (Serious) Adverse Event; mRNA: messenger RNA. 
Study laboratory at baseline and V11: sodium, potassium, calcium, creatinine, glomerular filtration rate (GFR), c-reactive protein, aspartate transaminase (AST), 
alanine transaminase (ALT), gamma glutamyltransferase (GGT), blood count, prothrombin time, partial thromboplastin time; study laboratory V2 to V10: sodium, 
potassium, creatinine, blood count; study laboratory V12: sodium, potassium, calcium, creatinine. 
a Hospitalization to a psychiatric hospital is not defined as SAE after V11. 
Fig. 2. Trial design.  
A. Hasan et al.                                                                                                                                                                                                                                  
Contemporary Clinical Trials Communications 17 (2020) 100537
5
the assessment of height, body weight and body mass index (BMI). 
Moreover, the Simpson-Angus scale (SiAS) is used to rate extrapyra-
midal side effects [39]. Due to the specific side-effect profile of spi-
ronolactone, special attention is paid regarding the assessment of 
potassium and creatinine levels, which are assessed every 2–3 days 
during the intervention period. Adverse events (AE), severe adverse 
events (SAE) and suspected unexpected serious adverse reactions 
(SUSAR) are documented following established definitions and legal 
requirements. The intensity of AEs is defined according to the common 
terminology criteria for adverse events (CTCAE Version 4.0, htt 
ps://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_Quic 
kReference_5x7.pdf). During the follow-up period (starts after V11), 
hospitalization to a psychiatric hospital due to the patient’s schizo-
phrenia disease was a priori defined not to be a SAE. 
Exploratory biological measures include the assessment of mRNA 
levels in peripheral blood lymphocytes to evaluate whether the inter-
vention modulates mRNA levels of NRG1 type I, II and III, and ERBB4-
cyt1 and cyt2 variants. Moreover, cortical excitability and plasticity 
using TMS and transcranial direct current stimulation are assessed in the 
model system of the motor cortex as in vivo marker of the excitation/ 
inhibition balance [40]. Both biological measures are optional. For TMS, 
patients have to sign an additional informed consent. 
2.6. Sample size justification and planned data analysis strategy 
SPIRO-TREAT is designed as a Phase IIb study. Since spironolactone 
is applied for the first time for this indication, no previous data is 
available to estimate the expected effect size. For the primary outcome 
(change of 2-back performance (sums of hits) before and after inter-
vention), assuming repeated measures ANOVA as analysis method, a 
type I error probability of α  0.05, a power of 1  β  0.8, three groups, 
two measurement time points (V1, V10), and a correlation between the 
measurements of r  0.4, medium effects of f  0.30 or higher can be 
detected for the within-subject factor time, for the between-subject 
factor group, and for interactions between time and group with a total 
sample size of 81 (27 participants per group) at V10. These calculations 
were performed with G*power 3.1.7 [41]. 
To confirm this theoretical framework, multiple analyses on Monte 
Carlo simulated data for 81 subjects (27 subjects for each of the three 
groups) at two measurement time points (V1, V10) were performed a) 
using a linear mixed model and b) using repeated measures ANOVA as 
analysis methods. From these analyses, the power for both factors and 
their interactions was sufficiently high for both methods (all 1–β  0.8). 
Moreover, it resulted that the power for the linear mixed model and for 
repeated measures ANOVA was identical for complete datasets at V1 and 
V10. 
The intention-to-treat (ITT) population includes all patients as ran-
domized. Assuming a drop-out rate of 10% during the intervention 
period, 90 patients are planned to be randomized. The per protocol (PP) 
population will include all participants without major protocol viola-
tions. All primary analyses will be performed on the ITT population. For 
the primary endpoint, a linear mixed model will be performed and in 
cases of significant ‘group x time’ interactions, post-hoc comparisons 
corrected for multiple testing will be performed. Continuous secondary 
endpoints will be analyses using linear mixed models and subsequent 
post-hoc tests if the requirements for this strategy are met (tested by 
Kolmogorov-Smirnov tests and Levene’s tests). In cases where the as-
sumptions of normality or variance homogeneity are violated, a mono-
tonic transformation of variables will be performed. If this first step is 
not successful, corresponding non-parametric tests will be used. Side- 
effects, AE and SAE will be analyzed with descriptive statistics and 
likelihood-ratio tests. Demographic information will be shown for each 
group separately. Dichotomous variables will be analyzed with 
likelihood-ratio tests and continuous variables will be analyzed using 
analyses of variance or respective non-parametric tests. An interim 
analysis is not planned. The statistician will be blinded for group during 
the phase of data-analyses. 
2.7. Organizational framework 
Organizational project management, safety management, moni-
toring and data management is performed by the Münchner Stud-
ienzentrum (MSZ), an academic clinical research organization at the 
Technical University of Munich, school of medicine. 
For safety monitoring, an independent safety monitoring board 
(SMB) is established. The underlying principles for the SMB are ethical 
and safety aspects for the patients. It is the task of the SMB to examine, 
whether the conducting of the study is still ethically justifiable, whether 
safety of the patients is ensured, and whether the process of the study is 
acceptable. For this, the SMB has to be informed regularly about patient 
recruitment, and the observed AEs. Occurring serious adverse events 
(SAEs) will be recorded in a study specific safety form and transferred 
into a safety database by the safety management (MSZ), which processes 
further SAE documentation in written form to the SMB, the Coordinating 
Investigator, the ethics committee and regulatory authority (BfArM). 
Trial sites must be experienced in clinical trials and must have adequate 
study infrastructure, e.g. a ‘good clinical practice’ (GCP)-trained Prin-
ciple Investigator (PI), PI deputy, study nurses and other trained study 
personal. 
The documentation of the study data in adherence to the GCP- 
guidelines and the clinical trial protocol is the responsibility of the 
investigator. Original data (source documents) remain in hospital 
medical record and information on the case report form must be trace-
able and consistent with the original data. Source documents are e.g. 
laboratory results. Original written informed consent signed by the pa-
tient is kept by the investigator and a signed copy will be given to the 
patient. No information in source documents about the identity of the 
patients will be disclosed. 
All study procedures agree with the guidelines of Good Clinical 
Practice (GCP) of the International Conference on Harmonization of 
technical requirements for registration of pharmaceuticals for human 
use (ICH), and the principles of the Declaration of Helsinki. All partici-
pating investigators agreed to adhere to the instructions and procedures 
described in the study protocol and thereby to adhere to the principles of 
ICH-GCP. The protocol and other required documents were reviewed 
and approved by the ethics committees and BfArM before study initia-
tion. Any amendments to the protocol other than administrative ones (of 
which the ethics committee and BfArM will merely be informed), must 
be reviewed and approved by both. Before inclusion of the first patient, 
the federal and state authorities will be informed about the study. The 
safety of the study will be judged by an independent committee of ex-
perts on regular basis, at a frequency of at least once a year via personal 
meeting or telephone conference. The members of this board will have 
access to the unblinded data, to all SAEs and SUSARs and to the inclu-
sion and drop-out rates. All members of the safety board are indepen-
dent from the sponsor. 
The current protocol version is 4.5 (17.10.2019, amendment 7.0). All 
protocol versions are available in German language at beate. 
schossow@mri.tum.de and alkomiet.hasan@med.uni-muenchen.de. At 
the time of this submission, the clinical trial is open for recruitment, 
which began in July 2015, and an actual number of 86 participants have 
been enrolled so far. 
3. Discussion 
The rational of SPIRO-TREAT (Add-on spironolactone for the 
treatment of schizophrenia) is derived from recent preclinical findings 
showing that the mineralocorticoid antagonist spironolactone can 
improve schizophrenia-relevant behavioral deficits in a Nrg1-transgenic 
mouse model by antagonizing increased ERBB4 receptor activity [26]. 
These findings support the notion that spironolactone may be efficient in 
an add-on clinical trial in schizophrenia patients. Thus, the 
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SPIRO-TREAT trial investigates for the first time whether the add-on 
treatment with the mineralocorticoid antagonist spironolactone is safe 
and effective to improve cognitive impairments and other symptom 
domains in patients with schizophrenia. Intriguingly, such an approach 
follows the idea proposed by the National Institute of Mental Health 
(NIMH) to identify risk-factors for mental-illness based on genetic and 
biological research, to repurpose known compounds in preclinical and 
animal studies and to conduct proof-of-concept trials in patients in 
academia settings [42,43]. This concept of repurposing of an existing 
drug or biological rather than the discovery of a new chemical entity has 
been continuously emphasized by NIMH as a promising potential way 
regarding the future of drug development for severe mental disorders 
[42,43]. 
As outlined above it is unlikely that compounds with novel modes of 
action for the treatment of schizophrenia, especially for difficult-to-treat 
domains like cognitive impairments or negative symptoms, will be 
developed by pharmaceutical companies [1]. Moreover, promising new 
antipsychotic compounds with alternative modes of actions recently 
failed before market launch [44,45]. Thus, drug repurposing as pro-
posed by the SPIRO-TREAT trial is one interesting possibility for an 
alternative pharmacological treatment approach in schizophrenia. In 
drug repurposing, approved drugs with a known history of their clinical 
application and potential side effects are tested for new uses, i.e. for new 
agonistic or antagonistic effects on molecular targets different from the 
ones they were previously developed for. A particular advantage of the 
repurposing of approved drugs is that these substances may therefore be 
immediately tested in a clinical trial, once they qualify for a novel target 
based on preclinical studies. 
The complete concept of SPIRO-TREAT follows an academic con-
ceptual framework of repurposing a drug from bench to bedside. First, 
members of our neurobiology lab (MCW, MJR) have established a co- 
culture assay system compatible with high-throughput-screening 
(HTS) utilizing the split tobacco etch virus (TEV) technology [46,47]. 
Second, we used this assay to identify an antagonist of ERBB4, namely 
spironolactone, from a library of approved drugs. Third, we were able to 
show that spironolactone decreases phosphorylation levels of ERBB4 in 
vitro and in vivo and normalizes altered excitation/inhibition of cortical 
projection neurons [26]. Finally, members of our group showed that 
applying spironolactone in Nrg1 transgenic mice ameliorates hyperac-
tivity, reverses sensorimotor gating and improves working memory 
[26]. Thus, SPIRO-TREAT can be viewed as the final step to meet the 
recommendations of a repurposing process that has been outlined by the 
NIMH for over a decade [42,43,48]. 
Overall, the risk-benefit evaluation pretends a short-term use in pa-
tients with schizophrenia. Long-term applications of medium to high 
doses of spironolactone may increase the risk for cardiac arrhythmia via 
high potassium levels and it could be expected, that this issue might be 
potentiated when combined for a longer period with antipsychotics. 
Furthermore, the long-term application may increase the risk for other 
consequences of hyperkaliemia, for gynecomastia and breast enlarge-
ment, for amenorrhea, and for blood count changes – among other 
relevant long-term side effects. Based on the application in transgenic 
mice models, which was also limited in time, and considering these 
outlined potential risks of long termed applications of spironolactone in 
patients with schizophrenia receiving antipsychotics as standard care, 
we therefore hypothesize that a targeted, but short-time application of 
spironolactone can restore altered NRG1-ERBB4 pathway activity. This 
will potentially lead to an improvement in working memory functions 
directly after and beyond the intervention phase. Thus, the overarching 
idea is that a deficient pathway activity can be normalized in the adult 
brain as it has been proposed in previous animal research [23,24]. Based 
on this rationale, we decided to apply the intervention for three weeks in 
our participants corresponding to the treatment duration in the previ-
ously published preclinical study [26]. 
The primary outcome of SPIRO-TREAT is the change in working 
memory according to the performance in n-back, precisely the change in 
sum of hits in the 2-back condition, as impairments in working-memory 
are core deficits in schizophrenia [29,49,50]. However, as schizophrenia 
is associated with impairments across several cognitive domains [50], 
SPIRO-TREAT investigates also the impact of the intervention on verbal 
working memory, complex visual scanning, motor speed, and the ability 
to shift strategies assessed as well as sustained and selective attention. 
These explorative assessments will allow for a comprehensive evalua-
tion whether spironolactone is effective in improving core cognitive 
impairments in schizophrenia or not. Moreover, several measures of 
psychopathology and functioning are also accessed in SPIRO-TREAT to 
test whether the assumed cognitive improvement is associated to a 
clinical improvement. 
Another important objective is the safety evaluation of high doses of 
spironolactone combined with antipsychotics. As most antipsychotics 
can induce QTc prolongation [51] and as cardiac arrhythmia due to high 
potassium levels are known side-effects of spironolactone, our trial will 
also strictly evaluate whether such an approach is safe in this popula-
tion. Therefore, blood sampling is performed three times per week and 
ECGs are performed before and after the intervention period to allow for 
a close monitoring of this potentially severe treatment complication. For 
that reason, SPIRO-TREAT is also testing two different high doses of 
spironolactone, namely 100 or 200 mg per day. In the case of a benefit of 
spironolactone over placebo, but no dose-dependent differences in ef-
ficacy, applying a low-dose would increase the safety as severe spi-
ronolactone side effects are clearly dose-dependent. 
4. Conclusion 
In summary, the aim of SPIRO-TREAT is to evaluate whether the 
application of three weeks of spironolactone add-on to an ongoing 
antipsychotic treatment can improve working memory deficits in pa-
tients with schizophrenia. Upon success, this study will introduce a new 
therapeutic principle in schizophrenia research based on a strong ge-
netic and biological background that is beyond the established concept 
of impairments in dopaminergic neurotransmission. 
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